Health technology company BioWave Corp reported on Tuesday the availability of the new US FDA cleared, over the counter version of its popular, non-opioid, patented, pain relief technology, the BioWaveGO.
The company said the BioWave products are Professional Athlete proven and US Military trusted and is currently used by most NFL, NBA, NHL, and MLB teams, 160+ college programmes, over 80 VA hospitals, as well as by pain doctors nationally.
BioWave is available in a wearable, non-prescription strength to help anyone in acute or chronic pain lead a fuller and active pain-free life. BioWave technology has been proven effective, significantly reducing pain from just one 30-minute treatment and comes with a 30-day money back guarantee. The US FDA-cleared, high-frequency neurostimulation technology delivers soothing therapeutic signals through the skin into deep tissue, blocking pain signals at the source, added the company.
In conjunction, the company stated the development of the new BioWaveGO OTC product is the natural evolution of a patented neurostimulator pain relief technology that was developed over more than ten years. BioWaveGo is available for purchase on the BioWave website and under Federal Supply Schedule contract number V797D-70205.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval